Some recent in vitro studies suggested that metformin may inhibit the growth of thyroid cancer cells through inhibition of the mammalian target of rapamycin (mTOR) pathway by activating the AMP-activated protein kinase (AMPK) [24] or by diminishing the growth stimulation by insulin [25]. Here, MTOR is linked to thyroid gland carcinoma.